Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying
September 30th 2024Panelists discuss how risk stratification tools like IPSS-M are applied in practice for lower-risk myelodysplastic syndromes, addressing prognosis communication and current treatment challenges for this patient group.
Read More
Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment
September 30th 2024Panelists discuss how myelodysplastic syndromes are diagnosed, classified, and managed, covering prevalence, symptoms, risk stratification tools, prognosis for lower-risk cases, and current treatment challenges.
Read More